FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	$D \subset$	20540
vasilington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER				Bio	Susuer Name and Ticker or Trading Symbol BioXcel Therapeutics, Inc. [BTAI] Date of Earliest Transaction (Month/Day/Year)						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (speci			vner	
(Last)	(F	irst)	(Middle)			06/26/2023							below)		below)	ьреспу
C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE					4. If /	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable) K Form filed by One Reporting Person				
(Street)	AVEN C	Т	06511				1055	1 (-	\ T	-4: l	-lili		Form f Persor		than One Repo	orting
(City)	(S	State)	(Zip)		$ _{\square}$	Chec	k this box	to inc) Transadicate that a trace defense cond	nsaction was	made pursua	ant to a con		on or written p	olan that is intend	ed to
		Tab	le I - No	n-Deriv	/ative	Sec	curities	s Ac	quired, D	isposed	of, or Be	neficial	ly Owned	t		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date			Code (Instr. 5)		red (A) or str. 3, 4 and	5. Amount of Securities Beneficially Owned Follo		Form: Direct	7. Nature of Indirect Beneficial Ownership		
								Code	/ Amoun	unt (A) or (D)		Transaci (Instr. 3	tion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) if any f ive (Month/Da	n Date,	Date, Transactio Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$17.52	06/26/2023		Ì	A		17,000		(1)	06/26/2033	Common Stock	17,000	\$0	17,000	D	

Explanation of Responses:

1. The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.

/s/ Richard I. Steinhart,

Attorney-in-Fact for Peter

<u>Mueller</u>

** Signature of Reporting Person Date

06/28/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.